EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against Northwest Biotherapeutics, Inc. – NWBO

NEW YORK--()--The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) resulting from allegations that the Company may have made false and misleading disclosures concerning its experimental cancer vaccine, DCVax-Direct.

On June 19, 2014, TheStreet.com published a report stating that, "[t]he prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct." MD Anderson Cancer Center and two other hospitals are conducting the DCVAX-Direct study with funding from Northwest Biotherapeutics. In the article, Dr. Aman Buzdar, vice president of clinical research at MD Anderson, commented that “"I have read the information that the company has put in the public domain. It is extremely unusual and inappropriate."

On this news, shares of Northwest Biotherapeutics fell $1.44 per share to $7.53, or more than 16%, in intraday trading on June 19, 2014, damaging investors.

The Rosen Law Firm is preparing a class action lawsuit on behalf of Northwest Biotherapeutics investors. If you purchased NWBO securities prior to June 19, 2014, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm P.A.
275 Madison Avenue, 34th Floor
New York, New York 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com

Contacts

The Rosen Law Firm P.A.
866-767-3653
Phillip Kim, Esq.
pkim@rosenlegal.com
or
Kevin Chan, Esq.
kchan@rosenlegal.com

Release Summary

Rosen Law Firm representing Northwest Biotherapeutics shareholders in securities fraud class action arising from alleged misleading statements about clinical trials of DCVAX-Direct - NWBO

Sharing

Contacts

The Rosen Law Firm P.A.
866-767-3653
Phillip Kim, Esq.
pkim@rosenlegal.com
or
Kevin Chan, Esq.
kchan@rosenlegal.com